The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
Abstract
The aim of the study was to investigate the effects of a dipeptidyl peptidase-4 (DPP-4) inhibitor, of metformin, and of the combination of the two agents, on incretin hormone concentrations. Active and inactive (or total) incretin plasma concentrations, plasma DPP-4 activity, and preproglucagon (GCG) gene expression were determined after administration of each agent alone or in combination to mice with diet-induced obesity (DIO) and to healthy human subjects. In mice, metformin increased Gcg expression in the large intestine and elevated the plasma concentrations of inactive glucagon-like peptide 1 (GLP-1) (9-36) and glucagon. In healthy subjects, a DPP-4 inhibitor elevated both active GLP-1 and glucose dependent insulinotropic polypeptide (GIP), metformin increased total GLP-1 (but not GIP), and the combination resulted in additive increases in active GLP-1 plasma concentrations. Metformin did not inhibit plasma DPP-4 activity either in vitro or in vivo. The study results show that metformin is not a DPP-4 inhibitor but rather enhances precursor GCG expression in the large intestine, resulting in increased total GLP-1 concentrations. DPP-4 inhibitors and metformin have complementary mechanisms of action and additive effects with respect to increasing the concentrations of active GLP-1 in plasma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Self-citationMannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Cellular and Molecular Mechanisms of Metformin Action
LaMoia, T. E., & Shulman, G. I. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa023 · Cited by 791
Metformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398
Self-citationFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
Maida, A., Lamont, B. J., Cao, X., & Drucker, D. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1937-z · Cited by 294
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S., Nicholls, A. W., Baker, D., Van Horn, S., Thomas, E., Rajpal, D., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 282
Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
Holst, J. J., Knop, F. K., Vilsbøll, T., Krarup, T., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-s227 · Cited by 280
Self-citationObesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Deacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
Self-citationBahne, E., Sun, E. W. L., Young, R. L., Hansen, M., Sonne, D. P., Hansen, J. S., Rohde, U., Liou, A. P., Jackson, M. L., de Fontgalland, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.93936 · Cited by 173
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Dunshee, D. R., Bainbridge, T. W., Kljavin, N. M., Zavala-Solorio, J., Schroeder, A. C., Chan, R., Corpuz, R., Wong, M., Zhou, W., Deshmukh, G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710582 · Cited by 158
Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids
Sansome, D. J., Xie, C., Veedfald, S., Horowitz, M., Rayner, C. K., & Wu, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13869 · Cited by 84
Panaro, B. L., Yusta, B., Matthews, D., Koehler, J. A., Song, Y., Sandoval, D. A., & Drucker, D. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100990 · Cited by 67
“The pleiotropic actions of metformin have also been linked to the acute GLP-1 secretion in preclinical studies [37] and in humans with type 2 diabetes [25].”
BackgroundIncretin dysfunction in type 2 diabetes: Clinical impact and future perspectives
Ahrén, B. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.001 · Cited by 64
Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
Self-citationTherapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“Interestingly, it has been observed that metformin actually increases at least meal-induced GLP-1 secretion and has at least an additive effect together with the DPP-4 inhibitors [104].”
BackgroundSelf-citationUeno, H., Tsuchimochi, W., Wang, H.-W., Yamashita, E., Tsubouchi, C., Nagamine, K., Sakoda, H., & Nakazato, M. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0113-3 · Cited by 38
Metadata
- Authors
- Migoya, E. M., Bergeron, R., Miller, J. L., Snyder, R. N. K., Tanen, M., Hilliard, D., Weiss, B., Larson, P., Gutierrez, M., Jiang, G., Liu, F., Pryor, K. A., Yao, J., Zhu, L., Holst, J. J., Deacon, C., Herman, G., Thornberry, N., Amatruda, J., Williams-Herman, D., Wagner, J. A., & SinhaRoy, R.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2010-11-03
- Volume
- 88
- Issue
- 6
- Pages
- 801-808
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2027744617
- Cited by
- 179
- References
- 7
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.